Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

A Reduced Intensity Conditioning Regimen With CD3-Depleted Hematopoietic Stem Cells to Improve Survival for Patients With Hematologic Malignancies Undergoing Haploidentical Stem Cell Transplantation

Blood and marrow stem cell transplant has improved the outcome for patients with high-risk hematologic malignancies. However, most patients do not have an appropriate HLA (immune type) matched sibling donor available and/or are unable to identify an acceptable unrelated HLA matched donor through the registries in a timely manner. Another option is haploidentical transplant using a partially matched family member donor.

Although haploidentical transplant has proven curative in many patients, this procedure has been hindered by significant complications, primarily regimen-related toxicity including GVHD and infection due to delayed immune reconstitution. These can, in part, be due to certain white blood cells in the graft called T cells. GVHD happens when the donor T cells recognize the body tissues of the patient (the host) are different and attack these cells. Although too many T cells increase the possibility of GVHD, too few may cause the recipient's immune system to reconstitute slowly or the graft to fail to grow, leaving the patient at high-risk for significant infection.

For these reasons, a primary focus for researchers is to engineer the graft to provide a T cell dose that will reduce the risk for GVHD, yet provide a sufficient number of cells to facilitate immune reconstitution and graft integrity. Building on prior institutional trials, this study will provide patients with a haploidentical (HAPLO) graft engineered to specific T cell target values using the CliniMACS system. A reduced intensity, preparative regimen will be used in an effort to reduce regimen-related toxicity and mortality.

The primary aim of the study is to help improve overall survival with haploidentical stem cell transplant in this high risk patient population by 1) limiting the complication of graft versus host disease (GVHD), 2) enhancing post-transplant immune reconstitution, and 3) reducing non-relapse mortality.

Study Overview

• Status: Completed
• Conditions: Hodgkin Lymphoma; Myelodysplastic Syndrome (MDS); Leukemia, Acute Lymphocytic (ALL); Juvenile Myelomonocytic Leukemia (JMML); Leukemia, Myeloid, Acute(AML); Leukemia, Myeloid, Chronic(CML); Hemoglobinuria, Paroxysmal Nocturnal (PNH); Lymphoma, Non-Hodgkin (NHL)
• Intervention / Treatment: Device: CliniMACS; Procedure: Stem cell transplantation; Drug: Fludarabine; Drug: Thioplex®; Drug: L-phenylalanine mustard; Drug: Mycophenolate mofetil; Drug: Rituxan™; Drug: Alemtuzumab; Drug: Cyclophosphamide; Drug: Anti-thymocyte globulin (Rabbit); Drug: G-CSF; Drug: Muromonab

Detailed Description

This study will explore the following objectives:

1. To assess if the event-free survival at one-year post-transplant for research participants with high-risk hematologic malignancies can be improved following HAPLO hematopoietic stem cell transplant (HSCT) using a graft depleted of CD3+ cells ex vivo and a reduced intensity-conditioning regimen.

Secondary objectives:

1. To estimate the one-year overall survival (OS) and disease-free survival (DFS) for research participants who receive this study treatment.
2. To estimate the cumulative incidence of relapse for research participants who receive this study treatment.
3. To estimate the rate of overall grade III-IV acute GVHD, and the rate and severity of chronic GVHD in research participants.
4. To estimate the incidence of non-hematologic regimen-related toxicity and regimen-related mortality in the first 100 days post-transplant.

Exploratory objectives:

1. To explore the biologic significance of soluble interleukin-2 receptor and immunologic state [quantitative lymphocyte studies, V beta spectratyping, T-cell receptor excision circles (TREC) assay] to predict the development of acute and chronic GVHD in these research participants.
2. To measure the pharmacokinetics of Campath-1H in pediatric HAPLO HSCT recipients

NOTE: This protocol originally used muromonab (OKT3) in the conditioning regimen to prepare participants for haploidentical HCT. After muromonab became unavailable from the manufacturer in 2010, muromonab was replaced by alemtuzumab (Campath-1H) for use in subsequent participants.

• Study Type: Interventional
• Enrollment (Actual): 73
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Tennessee
    • Memphis, Tennessee, United States, 38105
      • St. Jude Children's Research Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 21 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:(transplant recipient)

• Patients less than or equal to 21 years of age; may be greater than 21 years old if a current St. Jude patient or previously treated St. Jude patient within 3 years of completion of prior treatment.

• Must have one of the following diagnosis:

  • ALL high risk in second remission. Examples include relapse on therapy, first remission duration of less than or equal to 30 months, or relapse within 12 months of completing therapy.
  • ALL in third or subsequent remission.
  • ALL high risk in first remission. Examples include: induction failure, minimal residual disease greater than or equal to 1% marrow blasts by morphology after induction, persistent or recurrent cytogenetic or molecular evidence of disease during therapy requiring additional therapy after induction to achieve remission.
  • High-risk AML in first remission. Examples include monosomy 7, M6, M7, t(6;9), FLT3-ITD, or patients who have greater than or equal to 25% blasts by morphology after induction or who do not achieve CR after 2 courses of therapy (includes myeloid sarcoma).
  • Relapsed or persistent AML (less than or equal to 25% blasts in marrow by morphology).
  • AML in second or subsequent morphologic remission (includes myeloid sarcoma).
  • CML in first chronic phase with detectable molecular or cytogenetic evidence of disease despite medical therapy; or CML with a history of accelerated or blast crisis, now in chronic phase; or unable to tolerate tyrosine kinase inhibitor therapy.
  • Juvenile myelomonocytic leukemia (JMML).
  • Myelodysplastic syndrome (MDS).
  • Therapy related (secondary) AML, ALL, or MDS.
  • Hodgkin lymphoma after failure of prior autologous HSCT or unsuitable for autologous HSCT.
  • Non-Hodgkin lymphoma (NHL) in second complete remission (CR2) or subsequent.
• Has not received a prior allogeneic hematopoietic stem cell transplant.
• Does not have a suitable HLA-matched sibling donor available for stem cell donation.
• Does not have a suitable cord blood product or volunteer matched unrelated donor (MUD) available in the necessary time for stem cell donation.
• Has a suitable HLA partially matched family member available for stem cell donation.
• Cardiac shortening fraction greater than or equal to 25%.
• Creatinine clearance or glomerular filtration rate (GFR) greater than or equal to 40 ml/min/1.73 m^2.
• Forced vital capacity (FVC) greater than or equal to 40% of predicted value or a pulse oximetry value of greater than or equal to 92% on room air.
• Direct bilirubin less than or equal to 3 mg/dl.
• Age-dependent performance score of greater than or equal to 50.
• Serum glutamic pyruvic transaminase (SGPT) less than 3 times the upper limit of normal for age.
• Karnofsky or Lansky (age-dependent) performance score of greater than or equal to 50.
• No known allergy to murine products or human anti-mouse antibody (HAMA) results within normal limits.
• Not pregnant (confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment).
• Not breast feeding.

Inclusion criteria (stem cell donor):

• Partially HLA matched family member.
• At least 18 years of age.
• Human immunodeficiency virus (HIV) negative.
• Not pregnant (confirmed by negative serum or urine pregnancy test within 7 days prior to enrollment).
• Not breast feeding.

Inclusion criteria (transplant recipient - stem cell boost)

Has experienced one of the following disorders post-transplant:

• graft failure
• graft rejection
• delayed hematopoietic and/or immune reconstitution.

Exclusion: NA

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: High-Risk Hematologic Malignancies; Participants meeting eligibility criteria undergo haploidentical stem cell transplantation along with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (after January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF. Grafts from suitable haploidentical donors are processed using the CliniMACS system.

Device: CliniMACS; Miltenyi Biotec CliniMACS stem cell selection device; Procedure: Stem cell transplantation; An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.; Drug: Fludarabine; Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.; Other Names: Fludara; Drug: Thioplex®; Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.; Other Names: TESPA; TSPA; Thiotepa; Drug: L-phenylalanine mustard; Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.; Other Names: Phenylalanine mustard; Alkeran; L-PAM; L-sarcolysin; Melphalan; Drug: Mycophenolate mofetil; Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.; Other Names: MMF; CellCept®; Drug: Rituxan™; Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.; Other Names: Rituximab; Drug: Alemtuzumab; After January 2010, due to the unavailability of muromonab, transplant recipients received a conditioning regimen consisting of systemic chemotherapy and antibodies, including alemtuzumab.; Other Names: Campath-1H; Campath®; Drug: Cyclophosphamide; Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.; Other Names: Cytoxan; Drug: Anti-thymocyte globulin (Rabbit); Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.; Other Names: Thymoglobulin®; Rabbit ATG; Drug: G-CSF; Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.; Other Names: Filgrastim; Neupogen®; Drug: Muromonab; Prior to January 2010, transplant participants received a conditioning regimen consisting of systemic chemotherapy and antibodies, including muromonab. Muromonab became unavailable from the manufacturer at that time and was replaced by alemtuzumab.; Other Names: OKT3; Muromonab-CD3

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Event-free Survival (EFS)	To determine if one year event-free survival can be improved in pediatric patients undergoing a haploidentical transplant by using a reduced intensity conditioning regimen and a targeted dose T cell depleted donor product. EFS is defined as time from transplantation to the occurrence of relapse or death due to any cause. Patients who are alive at the time of analysis will be censored. The estimated percentage of participants with EFS at one-year post-transplantation is reported using Kaplan-Meier analysis.	one year post-transplant

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS)	Estimate the one-year overall survival (OS) for research participants who receive this study treatment. OS is defined as time from transplantation to death due to any cause. Patient who are alive at the time of analysis will be censored. The estimated percentage of participants with OS at one-year post-transplantation is reported using Kaplan-Meier analysis.	one year post-transplant
Disease-Free Survival (DFS)	Estimate the one-year disease-free survival (DFS) for research participants who receive this study treatment. DFS is defined as time from transplantation to the occurrence of relapse or death due to relapse. Patients who are alive at the time of analysis or die due to other causes will be censored at the time of their events. The estimated percentage of participants with DFS at one-year post-transplantation is reported using Kaplan-Meier analysis.	One year post-transplant
Incidence of Non-hematologic Regimen-related Toxicities	Estimate of the incidence of non-hematologic regimen-related toxicity and regimen-related toxicity in the first 100 days post-transplant. The percentage of participants are reported by maximum grade seen using binomial distribution. Participants were graded for toxicity using Common Terminology Criteria for Adverse Events version 3.0. In general, Grade 1 is mild, 2 is moderate toxicity but generally does not require treatment, 3 is severe enough to require treatment, 4 is life-threatening, and 5 means it was associated with death.	100 days post-transplant
Incidence of Regimen-related Mortality	The incidence of regimen-related mortality in the first 100 days post-transplant is estimated based on binomial distribution.	100 days post-transplant
To Estimate the Cumulative Incidence of Relapse for Research Participants Who Receive This Study Treatment.	The Cumulative Incidence of Relapse will be reported as the proportion of number of relapses since transplant to the total number of patients at risk at five years post-transplant.	five years post-transplant
To Estimate the Rate of Overall Grade III-IV Acute GVHD, and the Rate and Severity of Chronic GVHD in Research Participants.	The rate of Overall Grade III-IV Acute AVHD will be report as the proportion of patients who have Grade III-IV Acute GVHD to the total patients with transplant. The rate of Chronic GVHD will be report as the proportion of patients who have Chronic GVHD to the total patients with transplant. The Severity of Chronic GVHD will be reported using CTCAE grading system, as a number.	five years post-transplant

Collaborators and Investigators

• Sponsor: St. Jude Children's Research Hospital

Publications and helpful links

Helpful Links

• Clinical Trials Open at St. Jude
• St. Jude Children's Research Hospital

Study record dates

Study Major Dates

• Study Start (Actual): December 14, 2007
• Primary Completion (Actual): January 27, 2016
• Study Completion (Actual): February 6, 2020

Study Registration Dates

• First Submitted: November 29, 2007
• First Submitted That Met QC Criteria: November 29, 2007
• First Posted (Estimate): December 3, 2007

Study Record Updates

• Last Update Posted (Actual): April 14, 2020
• Last Update Submitted That Met QC Criteria: April 3, 2020
• Last Verified: October 1, 2019

More Information

Terms related to this study

• Keywords: High risk hematologic malignancies; Allogeneic stem cell transplant; Bone marrow transplant; Miltenyi Biotec CliniMACS stem cell selection device; Haploidentical stem cell transplant; Mismatched family member stem cell donor transplant; T cell depletion methodology; Campath-1H intravenous
• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Urologic Diseases; Urological Manifestations; Bone Marrow Diseases; Hematologic Diseases; Myeloproliferative Disorders; Urination Disorders; Anemia; Precancerous Conditions; Myelodysplastic-Myeloproliferative Diseases; Leukemia, Lymphoid; Proteinuria; Anemia, Hemolytic; Neoplasms; Lymphoma; Myelodysplastic Syndromes; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Preleukemia; Leukemia, Myelomonocytic, Juvenile; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hemoglobinuria; Hemoglobinuria, Paroxysmal; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Antineoplastic Agents, Immunological; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antitubercular Agents; Antibiotics, Antitubercular; Cyclophosphamide; Rituximab; Melphalan; Fludarabine; Mycophenolic Acid; Thiotepa; Thymoglobulin; Antilymphocyte Serum; Muromonab-CD3; Alemtuzumab; Mechlorethamine
• Other Study ID Numbers: HIFLEX; NCI-2011-03670 (Registry Identifier: NCI Clinical Trial Registration Program)